GeoVax Labs, Inc. has begun engaging with global health and preparedness organizations to explore potential future procurement of its GEO-MVA vaccine candidate for mpox and smallpox preparedness programs. The company has initiated discussions with international organizations that influence or directly procure mpox/smallpox vaccines, which play key roles in recommending or directly procuring vaccines for national preparedness stockpiles and international outbreak response programs.
This outreach reflects growing global recognition of the need to diversify supply of Modified Vaccinia Ankara vaccines used for protection against mpox and smallpox. Currently, global supply of MVA vaccines is concentrated in a single commercial manufacturer, creating potential vulnerabilities in global health security. Global preparedness programs for smallpox and mpox vaccines represent a potential multi-billion-dollar procurement market supported by national stockpiles, military preparedness programs, and international health organizations.
Governments have invested billions of dollars in medical countermeasure stockpiles over the past two decades, and demand for MVA-based vaccines is expected to further expand as mpox continues to emerge as a recurring global health threat. Recent mpox outbreaks have reinforced the understanding that mpox is not a single episodic event, but rather an evolving infectious disease threat with potential for continued geographic expansion and recurrence.
GeoVax believes that initiating engagement with procurement and preparedness organizations represents an important transition from development toward commercialization planning, reflecting growing confidence in the GEO-MVA program. The vaccine could contribute to global preparedness stockpiles following successful completion of the planned Phase 3 study, scheduled to initiate in the second half of 2026.
The GEO-MVA program has progressed through an extensive regulatory dialogue with the European Medicines Agency, culminating in scientific advice in support of an expedited development pathway based on a single immunobridging trial to the licensed MVA vaccine. The EMA carefully evaluated the scientific evidence over an extended period before confirming an expedited pathway.
In the United States, policymakers and defense stakeholders have increasingly recognized that no domestic manufacturing capability currently exists for MVA vaccines, a gap with implications for both civilian preparedness and military readiness. Establishing additional MVA manufacturing capability is increasingly viewed as an important component of global preparedness, with growing interest from public health organizations, governments, and defense stakeholders who recognize the strategic importance of supply diversification.
The discussions initiated by GeoVax occur amid growing policy dialogue regarding the strategic importance of expanding global MVA vaccine manufacturing capacity. GeoVax believes GEO-MVA has the potential to become a strategically important medical countermeasure supporting both global public health preparedness and national biodefense initiatives. For more information about the company's programs, visit https://www.geovax.com.
